Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (1): 51-59.doi: 10.3736/jcim20080111

• Original Experimental Research • Previous Articles     Next Articles

Antitumor activities of kushen flavonoids in vivo and in vitro

Ming-yu Sun1(), Jian Zuo2, Ji-feng Duan2, Jun Han3, Shi-ming Fan2, Wei Zhang2, Li-fang Zhu2, Ming-hui Yao4   

  1. 1. Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    2. Department of Pharmacology, Hutchison Medipharma Ltd, Zhangjiang Hi-Technology Park, Shanghai 201203, China
    3. Department of Pharmacognosy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
    4. Department of Pharmacology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2008-01-20 Published:2008-01-15
  • Contact: SUN Ming-yu E-mail:mysun248@hotmail.com

Objective:To explore the antitumor activities of kushen (Sophora flavescens) flavonoids (KS-Fs) in vivo and in vitro.

Methods:Cell proliferation was assayed by using methyl thiazolyl tetrazolium (MTT) method. H22 hepatocellular carcinoma and S180 sarcoma were induced in ICR mice. Lewis lung carcinoma was induced in C57BL/6 mice. H460 and Eca-109 tumor were induced in Balb/c nude mice by injecting 5×10 5 or 5×10 6 tumor cells in the right flank, respectively. 

Results:KS-Fs could inhibit the growth of a variety of human tumor cell lines (A549, SPC-A-1, NCI-H460, etc.) in vitro. The antitumor efficacies were confirmed in the mice models of H22, S180 and Lewis lung tumors and the nude mice models of human H460 and Eca-109 xenografted tumors. The oral or intravenous maximum tolerated dose of KS-Fs was more than 2.8 g/kg or 750 mg/kg respectively, far more than the oral medial lethal dose of kushen alkaloids (≤1.18 g/kg). No adverse reactions were observed.

Conclusion:These results suggest that KS-Fs or kurarinone may be developed as a novel antitumor agent.

Key words: Sophora flavescens, flavones, antineoplastic agents, mice

CLC Number: 

  • R286.91

Figure 1

High-performance liquid chromatograms and chemical structures of compounds in KS-Fs"

Figure 2

Cytotoxicity of marketed preparation of kushen alkaloids and KS-Fs in vitro **P<0.01, vs KS-Fs-treated group."

Table 1

Effects of KS-Fs on tumor and body weights in H22 hepatoma mice ($\bar{x}$±$s_{\bar{x}}$)"

Group n Body weight after tumor excision (g) Tumor weight (g) Inhibition rate (%)
Vehicle control 19 32.04±0.12 2.47±0.03 -
CTX-treated 10 32.23±0.23 0.47±0.02** 81.00
20 mg/kg KS-Fs-treated 10 32.88±0.22 1.40±0.08** 43.40
100 mg/kg KS-Fs-treated 10 32.69±0.18 0.83±0.05** 66.45
500 mg/kg KS-Fs-treated 10 33.77±0.10 0.52±0.02** 78.98

Figure 3

Effects of different doses of KS-Fs on the tumor of H22 hepatoma and S180 sarcoma in mice A: H22 hepatoma; B: S180 sarcoma."

Table 2

Effects of KS-Fs on tumor and body weights in S180 sarcoma mice ($\bar{x}$±$s_{\bar{x}}$)"

Group n Body weight after tumor excision (g) Tumor weight (g) Inhibition rate (%)
Vehicle control 10 29.65±0.51 2.91±0.11 -
CTX-treated 10 27.51±0.14 0.43±0.02** 85.11
60 mg/kg KS-Fs-treated 10 31.73±0.42 0.80±0.08** 72.52
200 mg/kg KS-Fs-treated 10 34.41±0.29* 0.52±0.05** 82.14

Table 3

Effects of KS-Fs on tumor and body weights in Lewis mice with lung carcinoma ($\bar{x}$±$s_{\bar{x}}$)"

Group n Body weight after tumor excision (g) Tumor weight (g) Inhibition rate (%)
Vehicle control 6 19.58±0.19 2.57±0.09 -
CTX-treated 6 18.38±0.07* 0.28±0.01** 88.96
60 mg/kg KS-Fs-treated 6 19.23±0.13 1.53±0.05** 40.26
200 mg/kg KS-Fs-treated 6 19.70±0.15 1.03±0.06** 59.74

Table 4

Effects of KS-Fs on the tumor weight of H460 in xenografted nude mice on the 25th day ($\bar{x}$±$s_{\bar{x}}$)"

Group n RTV Tumor weight (g) Inhibition rate (%)
Vehicle control 8 36.04±4.59 3.19±0.18 -
Cisplatin-treated 5 16.78±1.94** 1.69±0.06* 47.10
200 mg/kg KS-Fs-treated 8 19.24±1.03** 1.70±0.21* 46.80

Figure 4

Effects of KS-Fs or Kur on the relative tumor volume and relative body weight of H460 and Eca-109 xenografted tumors in nude mice *P<0.05, **P<0.01, vs vehicle control group; △P<0.05, △△P<0.01, vs cisplatin-treated group."

Table 5

Effects of KS-Fs or Kur on the tumor weight of Eca-109 in xenografted nude mice on the 22nd day ($\bar{x}$±$s_{\bar{x}}$)"

Group n RTV Tumor weight (g) Inhibition rate (%)
Vehicle control 6 9.08±1.06 0.53±0.04 -
Cisplatin-treated 6 5.25±0.63** 0.27±0.02** 49.81
200 mg/kg Kur-treated 6 5.21±0.63* 0.31±0.02** 41.29
50 mg/kg Kur-treated 6 6.59±0.60 0.50±0.08 4.92
200 mg/kg KS-Fs-treated 6 4.80±0.79* 0.30±0.02* 42.71
[1] State Administration of Traditional Chinese Medicine. Chinese herbal medicine. Shanghai: Shanghai Scientific and Technical Publishers. 1999: 634-643. Chinese.
国家中医药管理局.中华本草.上海科学技术出版社. 1999: 634-643.
[2] Kyogoku K, Hatayama K, Komatsu M . Constituents of Chinese crude drug "Kushen"( the root of Sophora flavescens Ait. ). Isolation of five new flavonoids and formononetin. Chem Pharm Bull. 1973 ; 21(12) : 2733-2738.
doi: 10.1248/cpb.21.2733
[3] Zhao YY j Wang B, Lei LM , et al. Constituents of the flavonoids from the roots of Sophora flavescens. Zhi WuXueBao. 1993; 35(4):304-306.
赵玉英, 王邠, 雷黎明 , 等. 苦参黄酮类成分的研究. 植物学报. 1993; 35(4):304-306.
[4] Ryu SY, Kim SK , No et al. A novel flavonoid from Sophora flavescens. Planta Med. 1996; 62(4):361-363.
doi: 10.1055/s-2006-957906 pmid: 17252471
[5] Woo ER, Kwak JH, Kim HJ , et al. A new prenylated flavonol from the roots of Sophora flavescens. J Nat Prod. 1998; 61(12):1552-1554.
doi: 10.1080/14786419.2012.761622
[6] Kuroyanagi M, Arakawa T, Hirayama Y , et al. Antibacterial and antiandrogen flavonoids from Sophora flavescens.[J] Nat Prod. 1999; 62(12):1595-1599.
doi: 10.1021/np990051d
[7] Kang TH, Jeong SJ, Ko WG , et al. Cytotoxic lavandu- lyl flavanones from Sophora flavescens.[J] Nat Prod. 2000; 63(5):680-681.
doi: 10.1021/np990567x
[8] Ko WG, Kang TH, Kim NY , et al. Lavandulyl flavonoids :a new class of in vitro apoptogenic agents from Sophora flavescens. Toxicol In Vitro. 2000; 14(5):429-433.
doi: 10.1016/S0887-2333(00)00041-2 pmid: 10963959
[9] Ding PL, Chen DF, Bastow KF , et al. Cytotoxic iso- prenylated flavonoids from the roots of Sophora flavescens. Helvetica Chimica Acta. 2004; 87(10):2574-2580.
doi: 10.1002/chin.200512244
[10] Kim YK, Min BS, Bae KH . A cytotoxic constituent from Sophora flavescens. Arch Pharm Res. 1997 ; 20(4):342-345.
doi: 10.1007/BF02976197 pmid: 18975176
[11] De Naeyer A, Vanden Berghe W, Pocock V , et al. Estrogenic and anticarcinogenic properties of kurarinone, a lavandulyl flavanone from the roots of Sophora flavescens. J Nat Prod. 2004; 67(11):1829-1832.
[12] Ha TJ, Yang SY, Jang DS , et al. Inhibitory activities of flavanone derivatives isolated from Sophora flavescens for melanogenesis. Bull Korean Chem Soc. 2001; 22(1):97-99.
[13] Kang SS, Kim JS , Xu YN, et al. Isolation of a new cer- ebroside from the root bark of aralia elata. J Nat Prod. 1999; 62(7):1059-106.
doi: 10.1021/np990018r pmid: 10425144
[14] Chung MY, Rho MC, Ko JS , et al. In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids irom Sophora flavescens. Planta Med. 2004; 70(3):258-260.
doi: 10.1055/s-2004-815545
[15] Carmichael J, Mitchell JB , DeGraff WG, et al. Chemo- sensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer. 1988; 57(6):540-547.
doi: 10.1038/bjc.1988.125 pmid: 2841961
[16] Bissery MC, Guenard D, Gueritte-Voegelein F , et al. Experimental antitumor activity of Taxotere( RP 56976,NSC 628503),a Taxol analogue. Cancer Res. 1991; 51(18):4845-4852.
pmid: 1680023
[17] Xu SY, Bian RL, Chen X. Pharmacological experimental methods. 3rd ed. People ' s Medical Publishing House. 2002: 1762. Chinese.
徐叔云, 卞如廉, 陈修 .药理实验方法学.第三版.人民卫生出版社. 2002: 1762.
[18] Sanceau J, Poupon MF, Delattre O , et al. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosf- amid. Oncogene. 2002; 21(50):7700-7709.
doi: 10.1038/sj.onc.1205881
[19] Hoi SU, Kim KH, Choi EJ , et al. P-glycoprotein (Pgp) does not affect the cytotoxicity of flavonoids from Sophora flavescens, which also have no effects on Pgp action. Anticancer Res. 1999; 19(3):2035-2040.
[20] Zhang LP , Jiang JK. Study of matrine on proliferation and differentiation of K562 cell line. Zhonghua Xue Ye XueZaZhi. 1999; 20(6):315-316. Chinese.
doi: 10.3760/j:issn:0253-2727.1999.06.010
张莉萍, 蒋纪恺 . 苦参碱对K562细胞增殖与分化作用的机制研究.中华血液学杂志. 1999; 20(6):315-316.
doi: 10.3760/j:issn:0253-2727.1999.06.010
[21] Zhou BG, Sun JZ, Su G , et al. Apoptosis of human breast cancer MCF-7 cells induced by oxymatrine. Zhonghua Shi Yan Wai Ke Za Zhi. 2002; 18(6):689-691. Chinese with abstract in English.
周炳刚, 孙靖中, 苏刚 , 等. 氧化苦参碱诱导人乳腺癌细胞MCF-7凋亡的实验研究.中华实验外科杂志. 2002; 18(6):689-691.
[22] Li LJ, Chen ZQ, Zheng YY , et al. Effects of oxymatrine on human ovarian cancer cell SKOV-3 in vitro. Shi Yong Zhong Liu Xue Za Zhi. 2003; 17(2):100-101. Chinese.
doi: 10.3969/j.issn.1002-3070.2003.02.009
李龙江, 陈志琼, 郑元义 , 等. 氧化苦参碱对人卵巢癌细胞SKOV-3体外活性的影响.实用肿瘤学杂志. 2003; 17(2):100-101.
doi: 10.3969/j.issn.1002-3070.2003.02.009
[23] Wang YS. Chinese herbal drug pharmacology and application. Beijing: People's Medical Publishing House. 1983: 638. Chinese.
王浴生 . 中药药理与应用.北京: 人民卫生出版社. 1983: 638.
[24] Li XR. Effects of 7 alkaloids from Kudouzi on immune function in mice. Zhong Cao Yao. 1987; 18(5):22-23. Chinese.
黎雪如 . 苦豆子的7种生物碱对小鼠免疫功能的影响. 中草药. 1987; 18(5):22-23.
[1] Khadem Ali Md., Ashraf Ayesha, Nath Biswas Nripendra, Kumar Karmakar Utpal, Afroz Shamima. Antinociceptive, anti-inflammatory and antidiarrheal activities of ethanolic calyx extract of Hibiscus sabdariffa Linn. (Malvaceae) in mice. Journal of Chinese Integrative Medicine, 2011, 9(6): 626-631.
[2] Yan-ming He, Wen-jian Wang, Wua-wei Chen, Jian Ying. Effects of Pollen Typhae total flavones on mRNA expressions of peroxisome proliferator-activated receptors in 3T3-L1 adipocytes. Journal of Chinese Integrative Medicine, 2008, 6(9): 939-941.
[3] Shao-Ying Lou, Yi Liu, Wei-Hua Chen, Jian Ying, Yan-Ming He, Wen-jian Wang. Pollen Typhae total flavones inhibit expression of interleukin-6 in C2C12 skeletal muscle cells cultured with palmitate. Journal of Chinese Integrative Medicine, 2008, 6(5): 488-491.
[4] Wei-liang Gu, Chang-xun Chen, Ying Wang. Comparative study of Scrophulariae and Aconite in inhibiting myocardial hypertrophy in rats and mice. Journal of Chinese Integrative Medicine, 2008, 6(4): 376-380.
[5] Ru-jiang Li, Shu-dong Qiu, Hong-xia Chen, Li-rong Wang. Immunomodulatory effects of Astragalus polysaccharide in diabetic mice. Journal of Chinese Integrative Medicine, 2008, 6(2): 166-170.
[6] Qing-shu Meng, Xiao-yan Zhu, Xiao-lu Tang, Bei Ma, Xin Ni. Effect of isoflavones in regulating the transcription of target genes through estrogen receptors. Journal of Chinese Integrative Medicine, 2007, 5(5): 577-580.
[7] Qiang Wang​, Kun-zheng Wang​, Guang-ye Wang​. Effects of soybean isoflavones on expression levels of osteoprotegerin and osteoprotegerin ligand mRNAs in bone tissues of ovariectomized rats. Journal of Chinese Integrative Medicine, 2006, 4(3): 303-306.
[8] Shan-feng Ma, Su-dong Guan, Yan Zhu. Effect of soybean isoflavones on heart function of rats with adriamycin-induced heart failure. Journal of Chinese Integrative Medicine, 2004, 2(4): 278-280.
[9] Ning Du, Yong Xu. Medical value of isoflavones. Journal of Chinese Integrative Medicine, 2003, 1(4): 296-300.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[4] Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[5] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[6] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[7] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[8] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[9] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[10] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50